Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

.1 million, or $1.07 per share for the same period in 2010.

"In 2011, we have made significant advances with our HCV nucleotide analogs," stated Schaefer Price, President and Chief Executive Officer. "At the recent AASLD meeting we reported consistently high SVR results from PSI-7977 and ribavirin dosed with or without interferon across genotypes 1, 2 and 3. This encouraging data in combination with PSI-7977's good safety profile and high barrier to resistance have enabled us to rapidly initiate the first interferon-free phase 3 program in the industry. We are excited to pursue an interferon-free regimen in phase 3 since interferon intolerability keeps most patients from being treated for their HCV. We anticipate filing for marketing approval in the US and Europe in the second half of 2013 and hope to be the first to introduce an interferon–free regimen in the marketplace."

Calendar Year 2012 Anticipated Milestones:-- Initiate Phase 3 POSITRON trial with PSI-7977 and ribavirin in patients with HCV GT2 or GT3 in the first quarter of 2012-- Report SVR24 HCV GT1 from Phase 2b PROTON study during the first quarter of 2012-- Report interim QUANTUM data in second quarter of 2012-- Report SVR12 from the 12-week treatment arm of ATOMIC during the second quarter of 2012.-- Report interferon-free ELECTRON data in subjects with HCV GT1 in the first half of 2012-- Initiate NEUTRINO, an interferon free, Phase 3 study of PSI-7977 and RBV for 12 weeks in subjects with all HCV genotypes who cannot take interferon in mid 2012.-- Report SVR12 from QUANTUM in the second half of 2012-- Report SVR12 from the arm with HCV genotype 2 or 3 subjects of Part 3 of ELECTRON during the third quarter of 2012.-- Report SVR12 from ATOMIC 24-week treatment arms during the second half of 2012.About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Md. , Dec. 24, 2014  United ... today that Medtronic, Inc. (NYSE: MDT ... the U.S. Food and Drug Administration (FDA) for ... implantable drug infusion system (including a newly developed ... (treprostinil) Injection delivered intravenously to patients with ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ... of the revenue and share analysis. , ...
(Date:12/24/2014)... On Friday, December 19, 2014, ... Omnibus and Continuing Resolution Appropriations Act of 2015, ... condition eligible to receive funding through the Congressionally ... Department of Defense (DoD). The Hydrocephalus Association (HA), ... Hill, is celebrating this victory for the over ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... The Netherlands , April 27, 2010 Immunovo,BV, a ... recent insights in oncology to develop novel,therapeutics, secures seed funding from Dutch ... , ... - Immunovo BV, a new,biotechnology company developing a novel technology platform ...
... Biotechnology Product Projects , , ... PARK, Md. , April 27 The Maryland Biotechnology Center, the ... and strengthen the state,s bioscience community, has enabled biotechnology product development projects to ... support. , , , ...
... Gage R&R of ... ... reports of quality failures in both the medical device and automotive industries, InterTech Development Company ... entire assembly and test systems, not just instruments. Having been called in to solve ...
Cached Biology Technology:Immunovo BV- A New Biotechnology Company is Announced 2Maryland Biotechnology Center Supports $270,000 in MIPS Projects 2Maryland Biotechnology Center Supports $270,000 in MIPS Projects 3Maryland Biotechnology Center Supports $270,000 in MIPS Projects 4Maryland Biotechnology Center Supports $270,000 in MIPS Projects 5InterTech Service to Counter Widely Reported Problems in Automotive, Medical Device and Other Industries Requiring Rigorous Quality Standards 2
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... one of the immune system,s key weapons against infection ... biliary atresia in infants, a disease where blocked bile ducts ... Cincinnati Children,s Hospital Medical Center also report that blocking a ... damage and may be a way to treat the most ...
... , , , ... Shopper Insights Conference, Perception Research Services International (PRS) and EmSense ... packaging research studies. The companies presented findings from a ... EmSense,s EmGear(TM) EEG unit to link package viewing patterns with ...
... The new research study led by scientists at ... that by improving overall ocean health, corals are better ... rising sea temperatures force corals to expel their symbiotic ... that is expected to increase in frequency as global ...
Cached Biology News:Scientists link immune system's natural killer cells to infant liver disease 2PRS And EmSense Partner To Integrate Bio-Sensory Measures In Packaging Research Studies 2Scripps-led study shows ocean health plays vital role in coral reef recovery 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... and IHC Protocol Development ,Antibody Titer ... in Animal or Human Cells and ... and Tissues ,Peroxidase, Alkaline Phosphatase, Immunogold, ... Electron Microscopy ,Protein Localization in Transgenic ...
Biology Products: